Biodexa Pharmaceuticals PLC
BDRX5.480USD
+0.240+4.78%
收盤 11/14, 16:00（美東）報價延遲15分鐘
33.95B總市值
--本益比TTM
關於 Biodexa Pharmaceuticals PLC 公司
Biodexa Pharmaceuticals PLC 是一家位於英國的臨牀階段生物製藥公司。該公司正在開發一系列產品，用於治療尚未滿足醫療需求的疾病。其技術包括 Biodexa Pharmaceuticals Q-Sphera、MidaCore 和 MidaSolve。Q-Sphera 技術專注於長效注射劑，使用專有的三維 (3D) 打印技術將藥物封裝到具有精確特性的生物可吸收聚合物微球中。MidaCore 技術平臺使用超小金納米顆粒 (GNP) 藥物偶聯物。MidaSolve Nano Inclusion 技術可溶解具有最小溶解度生物氫 (pH) 潛力的分子，從而擴展可用的給藥途徑，包括直接向腫瘤遞送。其產品線包括 MTX110、MTD201、MTD211（精神分裂症、MDD）、MTX223 和 MTD217。
Biodexa Pharmaceuticals PLC簡介
公司代碼BDRX
公司名稱Biodexa Pharmaceuticals PLC
上市日期Dec 08, 2014
CEOMr. Stephen A. Stamp
員工數量- -
證券類型Depository Receipt
年結日Dec 08
公司地址1 Caspian Point
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編CF10 4DQ
電話4401235888300
網址https://www.biodexapharma.com/
公司代碼BDRX
上市日期Dec 08, 2014
CEOMr. Stephen A. Stamp
Biodexa Pharmaceuticals PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暫無數據
地區USD
名稱
營收
佔比
Belgium
381.00K
100.00%
業務
地區
暫無數據
股東統計
更新時間: 10月2日 週四
更新時間: 10月2日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
其他
92.73%
持股股東
持股股東
佔比
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
其他
92.73%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
5.75%
Bank and Trust
1.12%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Hedge Fund
0.07%
Research Firm
0.02%
其他
91.86%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
27
38.43K
6.20%
+24.49K
2025Q2
36
46.40K
7.49%
+35.30K
2025Q1
38
272.70K
5.41%
+162.94K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Cavalry Fund I Management, LLC
17.52K
2.83%
+17.52K
--
May 20, 2025
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
UBS Switzerland AG
199.00
0.03%
-815.00
-80.37%
Jun 30, 2025
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
1.42K
0.23%
+793.00
+126.88%
Apr 01, 2024
GAMMA Investing LLC
1.35K
0.22%
+158.00
+13.23%
Sep 30, 2025
GS Capital Partners LLC
631.00
0.1%
+631.00
--
Apr 01, 2024
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
公告日期
類型
比率
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
Mar 16, 2023
Merger
4→1
查看更多
